ACHV vs. CDXS, RIGL, XOMA, VNDA, VSTM, SGMO, LXRX, RGLS, AGEN, and FBIO
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Codexis (CDXS), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), Regulus Therapeutics (RGLS), Agenus (AGEN), and Fortress Biotech (FBIO). These companies are all part of the "biotechnology" industry.
Achieve Life Sciences vs.
Achieve Life Sciences (NASDAQ:ACHV) and Codexis (NASDAQ:CDXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, community ranking, analyst recommendations and risk.
Codexis received 17 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. However, 70.46% of users gave Achieve Life Sciences an outperform vote while only 61.47% of users gave Codexis an outperform vote.
Achieve Life Sciences presently has a consensus target price of $14.80, suggesting a potential upside of 378.96%. Codexis has a consensus target price of $8.33, suggesting a potential upside of 66.67%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Achieve Life Sciences is more favorable than Codexis.
33.5% of Achieve Life Sciences shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 2.0% of Achieve Life Sciences shares are owned by company insiders. Comparatively, 2.1% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
In the previous week, Codexis had 6 more articles in the media than Achieve Life Sciences. MarketBeat recorded 9 mentions for Codexis and 3 mentions for Achieve Life Sciences. Codexis' average media sentiment score of 0.62 beat Achieve Life Sciences' score of 0.48 indicating that Codexis is being referred to more favorably in the news media.
Achieve Life Sciences has a net margin of 0.00% compared to Codexis' net margin of -96.35%. Codexis' return on equity of -71.56% beat Achieve Life Sciences' return on equity.
Achieve Life Sciences has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500. Comparatively, Codexis has a beta of 2.13, meaning that its stock price is 113% more volatile than the S&P 500.
Achieve Life Sciences has higher earnings, but lower revenue than Codexis. Codexis is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Codexis beats Achieve Life Sciences on 10 of the 18 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ACHV) was last updated on 1/18/2025 by MarketBeat.com Staff
Free ACHV Stock Alerts